News & Events

25

Feb2020

Sharing Responses to the Patented Medicine Prices Review Board (PMPRB) Draft Guidelines Consultation

/ PDCI, PMPRB
On November 21, 2019, the PMPRB published its draft Guidelines and launched a public consultation as a step towards implementing the recently amended Patented Medicines Regulations. Since then, the PMPRB has engaged with stakeholders to obtain feedback on its proposed pricing Guidelines. The consultation period closed on February 14, ... Read More

24

Feb2020

Status Summary of Innovative Medicine pCPA Negotiations as of January 31, 2020

/ pCPA, What's New
Each month the pCPA issues an update on the previous month’s negotiation activity. Below, you will find an overview of the new pCPA activity along with PDCI insights into recent developments for your interest. Summary of New pCPA Activity Since ... Read More

14

Feb2020

CADTH Releases Pharmaceutical Reviews Update – Issue 13

/ CADTH, PDCI, What's New
CADTH’s Pharmaceutical Reviews Updates are used to communicate new CDR and pCODR drug review process updates to the public. PDCI has outlined below the key highlights from the most recent update. For more information, please consult the CADTH website. In this Pharmaceutical Reviews Update, CADTH made program updates ... Read More

13

Feb2020

PDCI Analysis Estimates Impact of PMPRB Draft Guidelines to be up to $41.8 Billion

/ PDCI, PMPRB, Publications, What's New
Following the publication of the PMPRB Draft Guidelines on Nov 21, 2019, PDCI undertook an analysis to critically assess the impact of the PMPRB regulatory changes published in August 2019, as proposed to be implemented in the Draft Guidelines. Top-Line Summary The PMPRB regulatory changes and Draft ... Read More

29

Jan2020

PDCI’s New Associate Director, HTA and Clinical Evaluation

/ PDCI, What's New
PDCI is excited to announce the promotion of Andrea Lau to the position of Associate Director, HTA and Clinical Evaluation. Andrea has been with PDCI for over 3 years, and in that time has been invaluable ... Read More

15

Jan2020

Status Summary of Innovative Medicine pCPA Negotiations as of December 31, 2019

/ What's New
Each month the pCPA issues an update on the previous month’s negotiation activity. Below, you will find an overview of the new pCPA activity along with PDCI insights into recent developments for your interest. Summary of New pCPA ... Read More

14

Jan2020

PMPRB and “Zero-dollar” Sales

/ Blog, PDCI, PMPRB, What's New
W. Neil Palmer In its December 2019 NEWSletter[1], the Patented Medicine Prices Review Board (PMPRB) is “reminding” patentees that they are required under the Patent Act (the Act) and the Patented Medicines Regulations (the Regulations) to file all zero-dollar sales, referring specifically to free goods. This “reminder” is troubling ... Read More

13

Jan2020

CADTH Releases Pharmaceutical Reviews Update – Issue 12

/ CADTH, What's New
CADTH’s Pharmaceutical Reviews Updates are used to communicate new CDR and pCODR drug review process updates to the public. PDCI has outlined below the key highlights from the most recent update. For more information, please consult the CADTH website.  CADTH released new updates to economic Category 1 Requirements ... Read More

06

Jan2020

PMPRB Consultation Update and Patentee Webinar

/ PMPRB
Recently, the deadline for providing written submissions on the PMPRB’s proposed new Guidelines was extended until January 31, 2020. As part of the ongoing consultation process, the PMPRB has reserved three days in January for bilateral meetings with individual patentees: January 8, 9, and 10, 2020. Meetings will be scheduled on ... Read More

18

Dec2019

Happy Holidays from PDCI Market Access!

/ PDCI, What's New